Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8236 to 8250 of 8904 results

  1. Venous thromboembolism in adults: reducing the risk in hospital (QS3)

    This quality standard has been updated and replaced by NICE quality standard QS201.

    Withdrawn quality standard

  2. Dementia: independence and wellbeing (QS30)

    This quality standard has been updated and replaced by NICE quality standard 184. 

    Withdrawn quality standard

  3. Obesity in adults: prevention and lifestyle weight management programmes (QS111)

    This quality standard has been updated and replaced by NICE quality standard 212.

    Withdrawn quality standard

  4. Diabetes in adults (QS6)

    This quality standard is updated and replaced by the quality standards on type 1 diabetes in adults (QS208) and type 2 diabetes in adults (QS209).

    Withdrawn quality standard

  5. Obesity: clinical assessment and management (QS127)

    This quality standard has been updated and replaced by NICE quality standard 212.

    Withdrawn quality standard

  6. Glaucoma in adults (QS7)

    This quality standard has been updated and replaced by NICE quality standard 180.

    Withdrawn quality standard

  7. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    In development Reference number: GID-TA11511 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    In development Reference number: GID-TA11406 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    In development Reference number: GID-TA11491 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Type 2 diabetes: dulaglutide (ESNM59)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Withdrawn advice

  12. Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM62)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Withdrawn advice

  13. Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  14. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Withdrawn advice

  15. Moderately to severely active ulcerative colitis: adalimumab (ESNM6)

    This evidence summary has been replaced by NICE technology appraisal guidance 329.

    Withdrawn advice